Zeleciment rostudirsen

The 32-participant registrational expansion cohort was not powered for statistically significant functional comparisons. The reported functional analysis was post hoc, combined placebo participants from the registrational and multiple-ascending-dose cohorts, and reported nominal p values; the prespecified plan did not include formal hypothesis testing of functional endpoints. Optional late biopsies involved four participants, compared with three baseline samples. Cardiopulmonary findings were compared with natural history and reflected mixed dose exposures, not continuous 20 mg/kg treatment throughout follow-up. Observational associations involving residual dystrophin should not be treated as direct proof of benefit from therapeutically restored dystrophin.

The available evidence describes the design of an approximately 90-participant confirmatory trial, not completed efficacy or safety results. The population is restricted to ambulatory males aged 4–18 years, with a screening rise-from-floor threshold below 10 seconds and stable glucocorticoids for at least 24 weeks. Therefore, the planned population does not directly address non-ambulatory participants. The primary assessment is at Week 73, following the stated 72-week treatment period.

PROMOVI was open label and included 79 eteplirsen-treated and 30 untreated participants. Completion was reported for 78 of 79 treated participants and 15 of 30 untreated participants. The investigators considered the untreated cohort inappropriate for comparison because of genotype-related differences in clinical trajectory. The reported seven-fold dystrophin increase is relative to baseline and is not interchangeable with an absolute percentage of normal dystrophin. This was not a direct comparison with z-rostudirsen.

The study compared administrative data for 579 eteplirsen-treated participants with reconstructed patient-level information for 1,224 natural-history controls. It was not a randomized comparison. Consequently, the reported survival association cannot establish an unbiased causal treatment effect or a comparison with z-rostudirsen. Reconstruction of external controls and differences between data sources limit comparability.

This retrospective claims analysis pooled eteplirsen, casimersen, and golodirsen, rather than evaluating z-rostudirsen. Weighting addressed measured treatment-selection and censoring factors but does not make the comparison randomized. The 48-trial pooled estimate was HR 0.303 (95% CI 0.119–0.769), whereas the 66-trial estimate was HR 0.477 (95% CI 0.194–1.169). The latter interval includes 1. Results therefore depend on the pooled analysis and do not establish agent-specific effects.